

FOI 2199

12th February 2024

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

### **Question 1:**

**How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

### **Response:**

|                         |     |
|-------------------------|-----|
| • Adalimumab - Humira   | 8   |
| • Adalimumab Biosimilar | 182 |
| • Etrasimod             | 0   |
| • Filgotinib            | 0   |
| • Golimumab             | 1   |
| • Infliximab - Remicade | 0   |
| • Infliximab Biosimilar | 91  |
| • Mirikizumab           | 0   |
| • Ozanimod              | 0   |
| • Risankizumab          | 0   |
| • Tofacitinib           | 5   |
| • Upadacitinib          | 5   |
| • Ustekinumab           | 113 |
| • Vedolizumab           | 95  |

### **Question 2:**

**If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:**

### **Response:**

|                         |    |
|-------------------------|----|
| • Adalimumab - Humira   | 0  |
| • Adalimumab Biosimilar | 61 |
| • Etrasimod             | 0  |
| • Filgotinib            | 0  |
| • Golimumab             | 1  |
| • Infliximab - Remicade | 0  |

|                                |    |
|--------------------------------|----|
| • <b>Infliximab Biosimilar</b> | 49 |
| • <b>Mirikizumab</b>           | 0  |
| • <b>Ozanimod</b>              | 0  |
| • <b>Risankizumab</b>          | 0  |
| • <b>Tofacitinib</b>           | 5  |
| • <b>Upadacitinib</b>          | 3  |
| • <b>Ustekinumab</b>           | 35 |
| • <b>Vedolizumab</b>           | 55 |

Email: [FOI.team@southerntrust.hscni.net](mailto:FOI.team@southerntrust.hscni.net)